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Background: The salivary mucin MUC5B, present in (sero)mucous secretions including submandibular gland (SMG)
saliva, plays an important role in the lubrication of the oral mucosa and is thought to be related to the feeling of
dry mouth. We investigated if MUC5B levels in SMG saliva could distinguish between the presence or absence of
severe dry mouth complaints 12 months after radiotherapy (RT) for head-and-neck cancer (HNC).
Findings: Twenty-nine HNC patients with a residual stimulated SMG secretion rate of ≥0.2 ml/10 min at 12 months
after RT were analyzed. MUC5B (in U; normalized to 1) and total protein levels (mg/ml) were measured in SMG saliva at
baseline and 12 months after RT using ELISA and BCA protein assay, respectively. Overall, median MUC5B levels
decreased after RT from 0.12 to 0.03 U (p= 0.47). Patients were dichotomized into none/mild xerostomia (n= 12) and
severe xerostomia (n= 17) based on a questionnaire completed at 12 months. SMG and whole saliva flow rates
decreased after RT but were comparable in both groups. The median MUC5B level was higher in patients with no or
mild xerostomia compared to patients with severe xerostomia (0.14 vs 0.01 U, p= 0.22). Half of the patients with severe
xerostomia had no detectable MUC5B at 12 months after RT. No differences in total protein levels were observed.
Conclusions: Qualitative saliva parameters like MUC5B need further investigation in RT-induced xerostomia. This pilot
study showed a trend towards lower MUC5B levels in the SMG saliva of patients with severe xerostomia 12 months
after RT for HNC.
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Background
Xerostomia after radiotherapy (RT) for head-and-neck
cancer (HNC) has a major impact on quality of life in
HNC survivors [1,2]. Sparing of the parotid glands (PG)
using intensity-modulated radiotherapy (IMRT) signifi-
cantly improves parotid gland function in patients trea-
ted for HNC [3,4]. In some studies however, the use of
parotid gland-sparing RT alone did not improve patient-
reported xerostomia [4,5]. Probably the submandibular,
sublingual and minor salivary glands play an important
role in the subjective sense of moisture in between meals
[6]. They secrete glycoproteins (mucins) that cover and* Correspondence: T. Dijkema@umcutrecht.nl
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The larger salivary mucin MUC5B, present in (sero)mu-
cous secretions including submandibular gland (SMG)
saliva, is thought to be related to the perception of dry
mouth by retaining moisture in the mucosa [7,8].
Our hypothesis in this pilot study was that MUC5B
levels, as a qualitative parameter in human saliva, could
better explain xerostomia compared to quantitative sal-
iva measurements in RT patients. For that purpose, we
investigated if MUC5B levels in SMG saliva could distin-
guish between the presence or absence of severe dry
mouth complaints 12 months after RT for HNC.Patients
Twenty-nine patients were selected from a larger popu-
lation, included in prospective studies on salivary glandl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Dijkema et al. Radiation Oncology 2012, 7:91 Page 2 of 4
http://www.ro-journal.com/content/7/1/91function after RT for HNC at our department [9,10].
The selected patients all had a residual stimulated SMG
secretion rate of ≥0.2 ml/10 min at 12 months after RT.
The amount of 0.2 ml is the threshold for MUC5B ana-
lysis in saliva.
Saliva flow measurements
Techniques that were used for objective saliva measure-
ments have been described previously [3,9]. Stimulated
salivary flow rates were measured before treatment and
at one year after RT. Citric acid solution (5%) was ap-
plied on the anterior part of the tongue every 60 sec-
onds, for 10 minutes. Saliva near Wharton’s duct orifices
in the floor of the mouth was collected by gentle suction
with a micropipette, representing predominantly SMG
saliva but also varying amounts from the sublingual
glands (SLG). Stimulated PG saliva was collected separ-
ately using Lashley cups. After collection, saliva samples
were stored at -20 °C until analysis.
Saliva protein assays
MUC5B levels in the SMG saliva samples were deter-
mined by an enzyme-linked immunosorbent assay
(ELISA) as described previously [11,12]. The monoclonal
antibody F2 used for quantification of MUC5B specific-
ally recognises the terminal part of the carbohydrate
moiety, sulfo-Lewisa SO3-3Gal_1-3GlcNAc. This struc-
ture is present on MUC5B secreted by the SMGs, SLGs
and palatal (minor) salivary glands. MUC5B was quanti-
fied by comparison to unstimulated whole saliva from a
pooled sample of 10 healthy staff members of a dental
faculty with optimal oral health. Each study patient was
compared to the pooled sample of these healthy volun-
teers. MUC5B levels were expressed in relative units,
with the MUC5B concentration in the pooled saliva of
healthy volunteers normalized to 1. 1 Unit is approxi-
mately 230 μg/ml [13].
The total protein content (mg/ml) was measured in
SMG saliva using the BCA Protein Assay Reagent
(Pierce, Rockford, IL, USA) with bovine serum albumin
(BSA) as a standard.
Assessment of patient-reported xerostomia
All patients completed a xerostomia questionnaire (XQ)
before RT and 12 months after RT. The XQ contains
questions related to xerostomia and is scored on a 5-
point Likert scale. A score of ‘1’ means no complaints,
while a score of ‘5’ implies complaints are always
present. In this analysis, we utilized two questions
addressing the sensation of dry mouth during daytime
(‘Do you have a dry mouth during the day’) and night-
time (‘Do you have a dry mouth at night’). Xerostomia
was dichotomized into ‘severe’ (grade 4-5) or ‘none-to-
mild’ (grade 1-3). Patients who had grade 4-5 xerostomiaduring the day and/or the night at 12 months were
grouped together. Patients with no or mild complaints
(grade 1-3) during day- and nighttime were also grouped
together in the analyses.
Statistical analysis
Patient characteristics and MUC5B/protein levels were
reported using descriptive statistics (median, ranges or
proportions; where appropriate). Correlations were cal-
culated using Pearson’s correlation coefficient (r). Paired
samples obtained before and after RT were compared
using Wilcoxon signed ranks test. Subgroup differences
in saliva flow rate, MUC5B and protein levels were ana-
lyzed using the Mann–Whitney U test. Fisher’s Exact
test was used to compare proportions within cross tabu-
lations. All analyses were performed using SPSS version
16 (SPSS Inc, Chicago, IL, USA). A p value of <0.05 was
considered statistically significant.
Results
The 29 patients included in this pilot study had a mean
age of 58 years (range 35-82 yr) and 22 (76%) were male.
All patients had a squamous cell carcinoma of the head
and neck, with 19 oropharyngeal tumors (66%), 6 laryn-
geal (21%), 3 nasopharynx (10%) and 1 oral cavity (3%).
IMRT was used in 21 (72%) patients, the remainder was
treated with conventional (2D) techniques [9]. The mean
dose to the SMGs was 55.9 Gy (range 10.6-71.1 Gy).
Overall, the median MUC5B level decreased after RT
from 0.12 U to 0.03 U (p= 0.47). MUC5B levels at
12 months showed a very weak correlation with the
mean SMG dose in Gy (Pearson r= 0.18). The median
total protein content of SMG saliva decreased slightly
after treatment (1.00 and 0.82 mg/ml respectively,
p= 0.62).
Twelve months after RT, 17 patients had severe com-
plaints of dry mouth at day- and/or nighttime, 12
patients had no or mild complaints. The SMG and whole
saliva (PG+ SMG) flow rates decreased after RT but were
comparable in both groups at 12 months (Table 1).
No statistical differences were found in the baseline
MUC5B levels between the groups (median 0.12 versus
0.14 U for the group with and without severe xerosto-
mia, respectively) nor in the change from baseline in
each individual patient (calculated as ΔMUC5B: median
0.04 versus 0.11 U respectively, p= 0.9). ΔMUC5B
showed a small negative correlation with the SMG mean
dose in Gy (Pearson r= -0.26).
At 12 months, the median MUC5B was higher in
patients with no or mild xerostomia compared to
patients with severe complaints, although the difference
was not statistically different at the 0.05 level (Table 1).
The group with severe complaints was characterized
mainly by undetectable MUC5B levels and a number of
Table 1 Median saliva flow rates, MUC5B and total protein levels 12 months after RT in patients with and without
severe xerostomia during daytime and/or nighttime
No/mild xerostomia Severe xerostomia p
(n = 12) (n = 17)
SMG flow rate ml/10 min 0.69 0.80 0.66
WS flow rate (PG+ SMG) ml/10 min 3.35 2.80 0.82
MUC5B concentration U 0.14 0.01 0.22
Undetectable MUC5B * % 25 47 0.27
MUC5B x flow rate † μg/10 min 15.0 1.3 0.37
Total protein mg/ml 0.87 0.82 0.76
Abbreviations: SMG= submandibular gland, WS=whole saliva, PG=parotid gland, U=units; normalized to 1 for unstimulated saliva in healthy controls.
* MUC5B level in SMG saliva equal to 0.00 U at 12 months after RT.
† The MUC5B x flow rate product (in μg/10 min) was calculated by multiplying the MUC5B concentration (in U) and SMG flow rate (in ml/10 min) for each patient
at 12 months after RT and assuming 1 Unit is 230 μg/ml of MUC5B [13].
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and 123-fold increase in the MUC5B concentration from
baseline. Repeating the analyses without these two
extremes showed a borderline significant higher MUC5B
level in the patients with no or mild xerostomia (median
0.14 vs 0.00 U, p= 0.055) at 12 months.
When we combined the qualitative (MUC5B in U) and
quantitative (SMG flow rate in ml/10 min) measure-
ments for each individual patient by multiplying both
parameters (MUC5B x flow rate; Table 1) and assumed 1
Unit is 230 μg/ml of MUC5B [13], we found an approxi-
mate 10-fold lower value (in μg/10 min) in the group of
patients with severe complaints of dry mouth, although
statistical difference was not reached in this small study.
The median total protein content in SMG saliva after
12 months was similar in both groups.
Discussion
This pilot study did not show a statistically significant
difference in MUC5B levels in SMG saliva of patientsMUC5B levels in relation to xerostomia
no / mild severe
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Figure 1 Comparison of MUC5B levels (in U) in patients with
and without severe xerostomia 12 months after RT, measured
using ELISA. The horizontal line represents the median for each
group.with and without severe xerostomia 12 months after RT,
although a trend was observed towards higher MUC5B
levels in patients with fewer complaints of dry mouth.
Almost half of the patients with severe xerostomia had
no detectable MUC5B at 12 months after RT. The
results are therefore of interest and do need investiga-
tion within a larger cohort of patients. An ongoing pro-
spective study at our department, investigating the effect
of sparing the contralateral SMG on xerostomia after
RT, is expected to yield more SMG saliva samples for fu-
ture qualitative analyses [10].
As both subgroups in this study had comparable
amounts of saliva but differed in the severity of their
complaints, a case is made for qualitative saliva para-
meters rather than quantitative measurements in xeros-
tomia research. The high-molecular weight salivary
mucin MUC5B contains large carbohydrate groups that
are heterogeneous and include sulfated and sialylated
oligosaccharides, retaining large amounts of water. The
unique rheological properties of MUC5B contribute to
the formation of a thin salivary film and the resulting de-
mulcent coat is thought to hydrate and lubricate the soft
tissues of the mouth [14]. Serous acinar cells found in
the parotid glands do not produce mucins. The latter
may explain why, in RT for head-and-neck cancer, spar-
ing of the parotid glands alone does not seem to im-
prove patient-reported xerostomia [4].
Apart from the free MUC5B fraction measured in
SMG saliva in this study, there may be other mucin-
related factors that can explain xerostomia. First, in
stead of the free fraction, the amount of mucosa-bound
MUC5B may better explain which patients will complain
of a dry mouth. Pramanik et al. showed, that in (non-
RT) dry mouth patients unable to provide a measurable
unstimulated saliva sample (zero flow), MUC5B was
often still present on all mucosal surfaces [15]. There-
fore, mucins retained on the mucosa of dry mouth
patients are presumably less hydrated than in normal
subjects. In this regard, post-translational modifications
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(rather than mucin levels per se) could result in a
reduced water content of mucins and explain the dry
mouth sensation. Loss of MUC5B sulfation was observed
in the mucous acini from labial salivary glands of
patients with Sjögren syndrome and was unrelated to
alterations in saliva quantity [7]. To what extent these
findings can be extrapolated to patients with
radiotherapy-induced xerostomia needs to be investi-
gated. Third, differently glycosylated MUC5B species are
present in saliva. In single glandular secretions and even
in one secretory acinus different glycoforms are
expressed, pointing to a large heterogeneity in mucin
molecules [16]. Moreover, MUC5B from different glan-
dular sources have different rheological properties that
may influence fluid retention on mucosal surfaces [17].
In this study, a specific (sulfo)glycolysation motif (sulfo-
Lewisa) was detected, present on MUC5B secreted by the
SMGs, SLGs and palatal minor glands. Possibly, (absence
of ) other MUC5B glycoforms can better explain why
some patients with recovering SMG secretion after RT
complain of a dry mouth and others do not.
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